NCT06408194View on ClinicalTrials.gov

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
LeukemiaAcute Lymphoblastic Leukemia
Interventions
DRUG

CD22CART infusion

CD22CART will be administered after Standard of Care (SOC) administration of tisagenlecleucel.

DRUG

Tisagenlecleucel

All enrolled participants will receive lymphodepletion followed by standard of care tisagenlecleucel infusion.

Trial Locations (1)

94304

RECRUITING

Stanford University, Palo Alto

All Listed Sponsors
lead

Stanford University

OTHER